Trading Alert: Collegium Pharmaceuticals May See Increased Activity Thursday

On April 27, the FDA approved Collegium's abuse-deterrent oxycodone Xtampza ER for twice-daily dosing for pain patients who require around-the-clock, long-term opioid treatment. Xtampza is unique because the drug maintains its release profile even after being subjected to common methods of manipulation and abuse such as chewing or crushing.

Why Investors Should Care

The call will help investors understand where an opioid treatment such as Xtampza fits from the perspective of a high prescriber. This is also the type of information that can illuminate the drug's long-term potential. Collegium's new oxycodone formulation is also at the nexus of the debate between adequate pain treatment and the risks of addiction, which has been pushed to the forefront of the nation's consciousness as a result of the ongoing opiate epidemic. Investors will also obtain information on the target patient population, which is important in valuing the drug.

Related Link: Opioid Addiction: What To Do When A Loved One Is Hooked

What Will Be Discussed

The expert call will provide investors with a better understanding of the current opioid and pain management landscape and Collegium's positioning in a crowded market. It will also review what the likely impact of Xtampza ER will be on the overall opioid market and how the medication compares to other tamper-resistant forms of oxycodone that are currently on the market.

The call is scheduled for 9 a.m. ET on Thursday and is being facilitated by expert networking firm Slingshot Insights. At last check on Wednesday, shares were trading down a little less than 3 percent to $10.76.